Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$8.25
+0.6%
$7.03
$4.07
$18.86
$523.71M1.551.07 million shs1.30 million shs
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$9.25
$9.22
$3.46
$9.28
$420.52M1.3840,890 shs178,496 shs
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$7.77
+2.0%
$8.25
$2.18
$13.68
$495.41M0.96309,338 shs231,966 shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$1.74
+2.4%
$2.10
$0.92
$3.79
$428.45M1.383.06 million shs5.87 million shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
0.00%+12.24%+30.13%+33.06%-54.60%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.00%0.00%0.00%0.00%0.00%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
0.00%+20.57%+6.81%+26.26%+68.80%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.00%+10.13%-15.53%-18.31%-36.50%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
3.5525 of 5 stars
3.41.00.04.51.92.50.0
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
2.5257 of 5 stars
4.51.00.00.01.43.30.0
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.0152 of 5 stars
3.33.00.00.01.81.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
2.75
Moderate Buy$14.5075.76% Upside
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3.00
Buy$18.50138.25% Upside
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.67
Moderate Buy$5.00187.36% Upside

Current Analyst Ratings

Latest KIN, LXRX, CDMO, and LRMR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/3/2024
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/30/2024
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$7.00 ➝ $8.00
4/30/2024
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/30/2024
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$5.00
4/23/2024
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/11/2024
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/3/2024
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/3/2024
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$25.00
3/15/2024
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$25.00
3/7/2024
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$7.00
2/20/2024
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 5/5/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$149.27M3.51$0.15 per share53.49$3.02 per share2.73
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$42.16M9.97N/AN/A$1.75 per share5.29
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/A$1.86 per shareN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$1.20M357.05N/AN/A$0.38 per share4.58

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$260K-$0.27N/AN/A-13.10%-8.78%-3.61%6/19/2024 (Estimated)
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$36.95M-$0.85N/AN/AN/AN/A-38.83%-34.33%5/20/2024 (Estimated)
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$177.12M-$0.83N/AN/AN/A-8,311.12%-137.53%-70.04%8/1/2024 (Estimated)

Latest KIN, LXRX, CDMO, and LRMR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/14/2024Q4 2023
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.25-$0.30-$0.05-$0.30N/AN/A
3/11/2024Q4 2023
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.23-$0.20+$0.03-$0.20$0.68 million$0.70 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
N/AN/AN/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
0.04
0.46
0.31
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.19
7.02
7.02
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/A
9.49
9.49
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
1.07
5.60
5.58

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
97.16%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
66.89%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
91.92%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
74.70%

Insider Ownership

CompanyInsider Ownership
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
2.39%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
13.69%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
4.30%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
6.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
36563.48 million61.96 millionOptionable
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
6345.46 millionN/AOptionable
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
4263.80 million61.06 millionOptionable
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
285246.24 million229.49 millionOptionable

KIN, LXRX, CDMO, and LRMR Headlines

SourceHeadline
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Reaffirmed by Needham & Company LLCLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Reaffirmed by Needham & Company LLC
americanbankingnews.com - May 5 at 3:46 AM
Optimistic Buy Rating for Lexicon Pharmaceuticals Amid Strong Inpefa Sales Outlook and Efficient Financial ManagementOptimistic Buy Rating for Lexicon Pharmaceuticals Amid Strong Inpefa Sales Outlook and Efficient Financial Management
markets.businessinsider.com - May 4 at 4:14 AM
Lexicon Pharmaceuticals Reports Q1 Loss, Misses Revenue EstimatesLexicon Pharmaceuticals Reports Q1 Loss, Misses Revenue Estimates
markets.businessinsider.com - May 4 at 4:14 AM
Head to Head Analysis: Lexicon Pharmaceuticals (NASDAQ:LXRX) and AXIM Biotechnologies (OTCMKTS:AXIM)Head to Head Analysis: Lexicon Pharmaceuticals (NASDAQ:LXRX) and AXIM Biotechnologies (OTCMKTS:AXIM)
americanbankingnews.com - May 4 at 2:04 AM
Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives Hold Rating from Needham & Company LLCLexicon Pharmaceuticals (NASDAQ:LXRX) Receives Hold Rating from Needham & Company LLC
marketbeat.com - May 3 at 11:14 AM
Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
finance.yahoo.com - May 3 at 7:29 AM
Biomea Fusion GAAP EPS of -$1.09 misses by $0.02Biomea Fusion GAAP EPS of -$1.09 misses by $0.02
msn.com - May 3 at 2:29 AM
Leerink Partnrs Reaffirms "Outperform" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)Leerink Partnrs Reaffirms "Outperform" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX)
americanbankingnews.com - May 3 at 2:22 AM
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasted to Post Q1 2024 Earnings of ($0.13) Per ShareLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasted to Post Q1 2024 Earnings of ($0.13) Per Share
americanbankingnews.com - May 3 at 1:42 AM
Lexicon: Q1 Earnings SnapshotLexicon: Q1 Earnings Snapshot
victoriaadvocate.com - May 2 at 9:28 PM
Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ...Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ...
finance.yahoo.com - May 2 at 9:28 PM
LXRX Stock Earnings: Lexicon Pharmaceuticals Meets EPS, Misses Revenue for Q1 2024LXRX Stock Earnings: Lexicon Pharmaceuticals Meets EPS, Misses Revenue for Q1 2024
msn.com - May 2 at 9:28 PM
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue EstimatesLexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
zacks.com - May 2 at 7:11 PM
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateLexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
globenewswire.com - May 2 at 4:05 PM
Lexicon Pharmaceuticals (LXRX) Outperform Rating Reaffirmed at Leerink PartnrsLexicon Pharmaceuticals' (LXRX) Outperform Rating Reaffirmed at Leerink Partnrs
marketbeat.com - May 2 at 7:29 AM
Leerink Partners Initiates Coverage of Lexicon Pharmaceuticals (LXRX) with Outperform RecommendationLeerink Partners Initiates Coverage of Lexicon Pharmaceuticals (LXRX) with Outperform Recommendation
msn.com - May 1 at 3:21 PM
Lexicon Pharmaceuticals (NASDAQ:LXRX) Now Covered by Analysts at SVB LeerinkLexicon Pharmaceuticals (NASDAQ:LXRX) Now Covered by Analysts at SVB Leerink
americanbankingnews.com - May 1 at 3:50 AM
Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to "Sell" by StockNews.comLexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to "Sell" by StockNews.com
americanbankingnews.com - May 1 at 2:14 AM
Lexicon Pharmaceuticals (LXRX) to Release Earnings on ThursdayLexicon Pharmaceuticals (LXRX) to Release Earnings on Thursday
marketbeat.com - April 30 at 1:22 PM
Lexicon Pharmaceuticals CEO Lonnel Coats To RetireLexicon Pharmaceuticals CEO Lonnel Coats To Retire
markets.businessinsider.com - April 30 at 7:50 AM
Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at SVB LeerinkLexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at SVB Leerink
marketbeat.com - April 30 at 7:22 AM
Lexicon Pharmaceuticals, Inc.: Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon PharmaceuticalsLexicon Pharmaceuticals, Inc.: Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
finanznachrichten.de - April 29 at 2:11 PM
Lexicon Pharmaceuticals Chief Executive Lonnel Coats to Retire in JulyLexicon Pharmaceuticals Chief Executive Lonnel Coats to Retire in July
marketwatch.com - April 29 at 2:11 PM
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon PharmaceuticalsLonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
globenewswire.com - April 29 at 9:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Avid Bioservices logo

Avid Bioservices

NASDAQ:CDMO
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Kindred Biosciences logo

Kindred Biosciences

NASDAQ:KIN
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.
Larimar Therapeutics logo

Larimar Therapeutics

NASDAQ:LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Lexicon Pharmaceuticals logo

Lexicon Pharmaceuticals

NASDAQ:LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.